Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.

Slides:

Advertisements

Similar presentations

Effect of intensification of long-term highly active antiretroviral therapy (HAART) with raltegravir on proviral HIV-1 DNA in blood and gut associated.

Advertisements

POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.

New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway

Measuring the latent HIV Reservoir

Hiromi Imamichi, Robin L. Dewar, Da Wei Huang, Dun Liang, Catherine R. Rehm, Ellen Paxinos, Michael Brown, Yan Guo, Colleen Ludka, Colleen Hadigan, Richard.

Evaluating residual HIV reservoirs Background or why is this important? What can be measured? Where should we measure it? Conclusions.

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.

Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.

1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):

In vivo analysis of HIV replication and persistence in the myeloid compartment J. Honeycutt, A. Wahl, J. Foster, R.A. Spagnulo and J. Victor Garcia Division.

EARLY ANTIRETROVIRAL TREATMENT HIV Cure Research Training Curriculum (CUREiculum) Early Antiretroviral (ART) Treatment Module by: Scientific Leads: Dr.

Impact of Early Initiation of Combination Antiretroviral Therapy on Measures of Virus in Peripheral Blood of Vertically HIV-1-Infected Children Jason Brophy.

2014 “Towards an HIV Cure” symposium Melbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-nai ̈ ve individuals.

Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.

Measuring the latent HIV Reservoir

Strategies for Targeting and Eradicating the HIV Reservoir

Hematopoietic stem cell based gene therapy for HIV diseases

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.

HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,

Future directions in HIV basic science research The hunt for a cure.

HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.

Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.

Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.

HIV Cellular Pathogenesis III

Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens Giron, LB; Tenore, S; Gabriel, R; Janini,

Studies of HIV Eradication: a Case for Using NHP Models Guido Silvestri, MD Yerkes National Primate Research Center Emory University School of Medicine.

Chapter 17: HIV/AIDS. HIV/AIDS -HIV: Human Immunodeficiency Virus -AIDS: Acquired Immunodeficiency Syndrome -AIDS represents the end stage of infection.

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.

Viral Tissue Reservoirs Are Determined Early and Little Viral RNA Is Detected during Suppression in the Macaque Model Zandrea Ambrose, Ph.D. Division of.

1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.

Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,

Measuring the HIV reservoirs: new and improved methods Sarah Palmer Westmead Millennium Institute for Medical Research University of Sydney.

Effect of 24 Week Intensification with a CCR5-Antagonist on the Decay of the HIV-1 Latent Reservoir IAS HIV RESERVOIRS WORKSHOP, 16 & 17 JULY 2010, VIENNA.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.

The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.

Are we most likely to cure HIV with gene therapy? Sharon R Lewin Director, Infectious Disease Unit, Alfred Hospital Professor, Department of Medicine,

Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.

LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.

HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.

Sporadic excesses of unintegrated HIV DNA can occur in HIV+ patients on HAART Una O’Doherty University of Pennsylvania.

What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.

ImmunoPathogenesis of HIV Disease Overview of HIV Epidemic Basic biology of HIV-1 Stages of HIV Disease Viral and Cellular Dynamics after HAART HIV Therapy.

HBV (chronic) HIV ~400 million chronically infected

HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.

Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments S. Fourati 1, S. Lambert-Niclot 1, C. Soulie 1, M.

The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,

Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:

Immune reconstitution Anjie Zhen, PhD

2014 “Towards an HIV Cure” symposium Melbourne An Overview of HIV Cure Research in 2014 Diana Finzi, Ph.D. Director, Basic Science Program Division of.

The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.

Emory University School of Medicine Department of Medicine

A HIGHER FRACTION OF DRUG RESISTANT PROVIRUSES EXPRESS UNSPLICED HIV RNA DURING ART COMPARED TO THE ARCHIVAL WILD-TYPE PROVIRUSES THAT COMPRISE THE HIV-1.

HIV Cure: Current Status and Future Perspectives

Conflict of Interest No conflicts of interest to declare.

Feedback meeting September 2017

HEATHER Feedback Meeting

The block-and-lock approach

Volume 5, Issue 6, Pages (June 2002)

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection Lin Shen, MD, Robert F. Siliciano,

Keep control: Elite and post-treatment controllers

Presentation transcript:

Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium Institute for Medical Research University of Sydney

Definitions Residual Viremia: Persistent HIV RNA measured in plasma at levels below the limit of detection of the standard clinical assay (20-50 copies/ml). Viral Reservoir: A viral reservoir is an anatomical site or cell type in which a replication-competent form of HIV persists, accumulating with more stable properties than the circulating pool of actively replicating virus. This HIV can persist even during effective therapy.

Time (days) Time (days) Plasma HIV-1 RNA (copies/ml) 22 ± 6 c/ml 4 ± 2 c/ml Viremia Persists after Suppression by Antiretroviral Therapy Start Therapy (d4T/3TC/efavirenz) bDNA bDNA <75 copies/ml Single-Copy Assay Single-Copy Assay < 1 copy/ml Palmer et al. JCM 2003 Maldarelli et al. PLoS Path 2007

Biphasic decline in persistent viremia over 7 years of treatment 11.6 copies/ml half-life=39 weeks 1.5 copies/ml 720 study assay limit 720 study Palmer et al. PNAS 2008 half-life= ∞

Persistent HIV Infection The IAS Scientific Working Group on HIV Cure: Nature Reviews Immunology 2012 Palmer et al. JIM 2011

Persistent HIV Infection

Measuring Persistent HIV Where to Measure Persistent Virus?  Peripheral Blood Plasma Cells: RNA versus DNA  Tissue Compartments T cells Other cell types RNA versus DNA  Role of Replication Defective HIV CNS/CSF

Measuring Persistent HIV Culture assay : IUPM Lewin & Rouzioux, AIDS 2011 Rouzioux & Richman, 2012

Measuring Persistent HIV Infection MeasurementAdvantagesDisadvantages HIV RNA in PlasmaRelatively inexpensiveDifficult to separate reservoir expression vs HIV replication, some positive samples undetectable, may not be representative of intracellular HIV RNA and DNA levels Infectious Virus: estimates the number of infectious units of HIV per million mononuclear cells (IUPM) Only direct measurement of replication competent virus or number of proviruses capable of productive infection Requires large quantities of cells, $$$, large error, often impossible to detect changes in reservoir size Total HIV DNA (Peripheral Blood or Tissue Compartments) Inexpensive, easyUnintegrated HIV DNA contributes to signal unless patients are on HAART for 1-3 years. A lot of virus is defective. Integrated HIV DNA (Peripheral Blood or Tissue Compartments) excludes unintegrated HIV DNA, less error than IUPM Requires at least a million cells, complex assay, defective provirus

Persistent HIV Infection in Tissue CNS/CSF

Persistent HIV Infection in Tissues Svicher et al. Curr HIV/AIDs Rep. 2014

Looking Ahead Does a “cure” require the total absence of HIV RNA and DNA? If not, then new more sensitive assays will be needed to differentiate between replication competent and non-replicating virus. Must all potential reservoirs be analyzed? If not, are we confident that certain reservoirs are determinative of cure/remission? With advances in curative strategies, will our current sensitive assays provide sufficient confidence to stop HIV therapy in patients showing a near absence of HIV RNA and DNA? Looking ahead, to determine the effectiveness of curative strategies, our field will need to develop a more standardized assay system which is sensitive, efficient, less costly, and adoptable in local settings.